Latest & greatest articles for methylphenidate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on methylphenidate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on methylphenidate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for methylphenidate

1. Methylphenidate hcl (Foquest)

Methylphenidate hcl (Foquest) Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you are accessing the Clinical

2020 Health Canada - drugs and medical devices

2. Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study (Abstract)

Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study The benefits of long-term use of methylphenidate treatment in children and adolescents with attention deficit hyperactivity disorder (ADHD), as frequently prescribed in clinical practice, are unclear. The authors investigated whether methylphenidate remains beneficial after 2 years of use.Ninety-four children and adolescents (ages 8-18 years) who had been (...) treated in regular care with methylphenidate for more than 2 years were randomly assigned to double-blind continuation of treatment for 7 weeks (36 or 54 mg/day of extended-release methylphenidate) or gradual withdrawal over 3 weeks, to 4 weeks of placebo. The primary outcome measure was the investigator-rated ADHD Rating Scale (ADHD-RS); secondary outcome measures were the investigator-rated Clinical Global Impressions improvement scale (CGI-I) and the Conners' Teacher Rating Scale-Revised: Short

2019 EvidenceUpdates

3. Methylphenidate (Ritalin and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects

Methylphenidate (Ritalin and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects Prescrire IN ENGLISH - Spotlight ''Methylphenidate (Ritalin° and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects'', 1 June 2019 {1} {1} {1} | | > > > Methylphenidate (Ritalin° and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Methylphenidate (Ritalin° and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects FEATURED REVIEW Methylphenidate is an amphetamine-like psychostimulant used in attention deficit hyperactivity disorder (ADHD). Recent studies have revealed important data about the consequences of in utero exposure

2019 Prescrire

4. Methylphenidate (Ritalin) as a means of controlling classroom behaviour

Methylphenidate (Ritalin) as a means of controlling classroom behaviour Prescrire IN ENGLISH - Spotlight ''Methylphenidate (Ritalin°) as a means of controlling classroom behaviour'', 1 May 2019 {1} {1} {1} | | > > > Methylphenidate (Ritalin°) as a means of controlling classroom behaviour Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight (...) Methylphenidate (Ritalin°) as a means of controlling classroom behaviour Too many children are overdiagnosed with attention deficit hyperactivity disorder (ADHD) simply because they are the youngest in the class and so tend to be more easily distracted and disruptive. Children are diagnosed with attention deficit with or without hyperactivity when they exhibit various non-specific symptoms such as difficulty concentrating in class, fidgetiness and impulsivity. The boundaries are unclear. At best

2019 Prescrire

5. Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. Full Text available with Trip Pro

Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. The prescription use of the stimulants methylphenidate and amphetamine for the treatment of attention deficit-hyperactivity disorder (ADHD) has been increasing. In 2007, the Food and Drug Administration mandated changes to drug labels for stimulants on the basis of findings of new-onset psychosis. Whether the risk of psychosis in adolescents and young adults with ADHD differs among various stimulants has not been extensively (...) studied.We used data from two commercial insurance claims databases to assess patients 13 to 25 years of age who had received a diagnosis of ADHD and who started taking methylphenidate or amphetamine between January 1, 2004, and September 30, 2015. The outcome was a new diagnosis of psychosis for which an antipsychotic medication was prescribed during the first 60 days after the date of the onset of psychosis. To estimate hazard ratios for psychosis, we used propensity scores to match patients who

2019 NEJM

6. Methylphenidate

. Methylphenidate (also known as Ritalin ®) is a drug that is used in the treatment of attention deficit / hyperactivity disorder (ADHD) in children, adolescents and adults. Modafinil ( Vigil ®) is a drug used in the treatment of narcolepsy (sleeping sickness). In the study. These substances are given in the study only once and in the dosages in which is also 2014 Follow us: © 2019 Trip Database Ltd. company number 04316414. Trip is proud to be made in the UK. (...) Methylphenidate Top results for methylphenidate - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3

2018 Trip Latest and Greatest

7. Prevalence of nonmedical use of prescription-type opioids, methylphenidate, and sedative-hypnotics among university students in the south of Iran: a regression analysis Full Text available with Trip Pro

Prevalence of nonmedical use of prescription-type opioids, methylphenidate, and sedative-hypnotics among university students in the south of Iran: a regression analysis Nonmedical use of prescription drugs needs particular attention. The aim of this study was to determine the prevalence of prescription-type opioids, methylphenidate and sedative-hypnotics use, and related factors in university students.In this cross-sectional study, 524 students of Hormozgan University of Medical Sciences were (...) was performed using Chi-square test, Fisher exact test, independent-samples t-test and binary logistic regression in SPSS 16 software. The level of significance was 0.05.The last year prevalence of prescription-type opioids, methylphenidate and sedative-hypnotics use was 16.1%, 3.3%, and 10.3%, respectively. The final model of logistic regression indicated hookah use (OR=2.5), methylphenidate use (OR=4.5), sedative-hypnotics use (OR=2.7), and were associated with students' prescription-type opioids use

2018 Electronic physician

8. Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer`s Disease: A Double-Blind, Randomized, Placebo-Controlled Trial Full Text available with Trip Pro

Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer`s Disease: A Double-Blind, Randomized, Placebo-Controlled Trial Apathy is a common behavioral problem in Alzheimer's disease. Apathy has profound consequences, such as functional impairment, higher service utilization, higher caregiver burden, and increased mortality. The authors' objective was to study the effects of methylphenidate on apathy in Alzheimer's disease.A 12-week, prospective, double-blind (...) , randomized, placebo-controlled trial (methylphenidate versus placebo) was conducted in community-dwelling veterans (N=60) with mild Alzheimer's disease. The primary outcome for apathy (Apathy Evaluation Scale-Clinician) and secondary outcomes for cognition (Mini-Mental State Examination, Modified Mini-Mental State Examination), functional status (activities of daily living, instrumental activities of daily living), improvement and severity (Clinical Global Impressions Scale [CGI]), caregiver burden

2017 EvidenceUpdates

9. Methylphenidate extended-release oral suspension for the treatment of attention-deficit/hyperactivity disorder: a practical guide for pharmacists Full Text available with Trip Pro

Methylphenidate extended-release oral suspension for the treatment of attention-deficit/hyperactivity disorder: a practical guide for pharmacists Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that affects children, adolescents, and adults worldwide. The purpose of this review was to inform pharmacists of the numerous options to treat ADHD, with a focus on one of the more recently approved formulations, methylphenidate extended-release oral suspension (MEROS (...) ). Symptoms of ADHD can negatively impact an individual's health and quality of life and impair function in multiple settings. Psychostimulants such as methylphenidate- and amphetamine-based agents are first-line pharmacologic treatments for ADHD. However, there are multiple formulations, including immediate release (administered two to three times/day), solid extended release (ER), or transdermal patch. MEROS is a once daily, long-acting liquid preparation that has demonstrated favorable safety

2017 Integrated pharmacy research & practice

10. Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: A double-blinded randomized clinical trial Full Text available with Trip Pro

Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: A double-blinded randomized clinical trial In some children with ADHD, sub-optimal levels of various nutrients including PUFA especially omega-3 has been observed, and contradictory reports exist on the results of studies conducted on the positive therapeutic effects of PUFA in patients with ADHD.The aim of this study was to investigate the effectiveness of methylphenidate and PUFA on treatment of patients (...) with ADHD in Zahedan, Iran.In this clinical trial, 40 children between 6 and 12 years of age with ADHD were investigated in Zahedan in 2014. Patients were randomly divided into two groups of methylphenidate plus PUFA and methylphenidate plus placebo. ADHD rating scale was filled before and after the study for patients of both groups. Finally, data were analyzed using SPSS18, paired-samples t-test and chi-square.Mean age of patients was 2.9±1.8 years. Thirty-three children (82.5%) were boys and seven

2017 Electronic physician Controlled trial quality: uncertain

11. The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder

The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder Article Text Methods

2017 Evidence-Based Medicine

12. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. Full Text available with Trip Pro

Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study.  To determine whether treatment with methylphenidate in children and young people with attention-deficit/hyperactivity disorder (ADHD) was associated with cardiovascular events. Self controlled case series analysis. Nationwide health insurance database, 1 January 2008 to 31 December 2011, in South Korea. 1224 patients aged (...) ≤17 who had experienced an incident cardiovascular event and had had at least one incident prescription for methylphenidate. A recorded diagnosis (either a primary or secondary cause) of any of the following cardiovascular adverse events: arrhythmias (ICD-10 (international classification of diseases, 10th revision) codes I44, I45, I47, I48, I49), hypertension (codes I10-I15), myocardial infarction (code I21), ischemic stroke (code I63), or heart failure (code I50). Incidence rate ratios were

2016 BMJ

13. Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater Full Text available with Trip Pro

Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater Article Text Perspective Methylphenidate for ADHD in children and adolescents: throwing the baby out

2016 Evidence-Based Mental Health

14. Evidence on methylphenidate in children and adolescents with ADHD is in fact of ?very low quality? Full Text available with Trip Pro

Evidence on methylphenidate in children and adolescents with ADHD is in fact of ?very low quality? Evidence on methylphenidate in children and adolescents with ADHD is in fact of ‘very low quality’ | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Evidence on methylphenidate in children and adolescents with ADHD is in fact of ‘very low quality’ Article Text Perspective Evidence on methylphenidate in children and adolescents with ADHD

2016 Evidence-Based Mental Health

15. Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder

identified regarding the duration of dosage effect for methylphenidate SR for patients with attention deficit hyperactivity disorder. Tags attention deficit disorder with hyperactivity, dexamfetamine, dexedrine, dextroamphetamine, mental health, methylphenidate, ritalin, Concerta, time course Files Rapid Response Summary of Abstracts Published : September 2, 2015 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter: (...) Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder | CADTH.ca Find the information you need Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder Duration of Dosage Effect for Methylphenidate SR

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

16. Methylphenidate: adverse cardiovascular effects

Methylphenidate: adverse cardiovascular effects Prescrire IN ENGLISH - Spotlight ''Methylphenidate: adverse cardiovascular effects '', 1 June 2015 {1} {1} {1} | | > > > Methylphenidate: adverse cardiovascular effects Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Methylphenidate: adverse cardiovascular effects Methylphenidate (Ritalin° and other (...) brands) exposes patients to severe adverse effects. It should only be envisaged in cases of severe behavioural disorder, at the minimum effective dose and under supervision. Methylphenidate is prescribed for hyperactive children with attention deficit disorder and in some cases of narcolepsy (uncontrollable tendency to fall asleep). Its adverse effects include neuropsychological and cardiovascular disorders, retarded growth in children, abuse and dependence. Methylphenidate belongs to the family

2015 Prescrire

17. Methylphenidate

Methylphenidate USE OF METHYLPHENIDATE IN PREGNANCY 0344 892 0909 USE OF METHYLPHENIDATE IN PREGNANCY (Date of issue: January 2018 , Version: 3 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Methylphenidate is a central nervous system stimulant (...) used in the management of attention deficit hyperactivity disorder (ADHD). It is also used off-license in the treatment of narcolepsy. The data regarding therapeutic use of methylphenidate do not suggest a significant increase in overall congenital or cardiac malformation rates, although a single study found an increased risk of conotruncal and major arch anomalies following exposure in utero. Increased risks of spontaneous abortion with methylphenidate use in early pregnancy and low Apgar score

2014 UK Teratology Information Service

18. Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability

Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability Article Text Children & Adolescents Methylphenidate reduces ADHD symptoms in children with severe ADHD

2013 Evidence-Based Mental Health

19. [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review]

[Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] Jang BH, Lee HY, Jung YJ, An JH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Jang BH, Lee HY, Jung YJ, An JH. [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] Seoul: National Evidence-based Healthcare Collaborating Agency (NECA). NECA-C-12-007. 2012 Authors' conclusions The research was carried out using the basic existing systematic review framework suggested by the Agency for Healthcare Research and Quality (AHRQ 2009

2012 Health Technology Assessment (HTA) Database.

20. Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD

Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD Article Text Therapeutics Review

2012 Evidence-Based Mental Health